Pfizer is moving forward with plans to seek regulatory approval for its Lyme disease vaccine candidate, even after the shot failed to meet the statistical endpoint in a late-stage clinical trial. The decision underscores the company’s confidence in the vaccine’s real-world potential—and highlights the complexities of vaccine development.

Why the Trial “Failed”—But Still Matters

The vaccine, developed with partner Valneva, did not meet its primary statistical endpoint because too few participants in the trial actually contracted Lyme disease.

This made it difficult to achieve the statistical certainty regulators typically require. However, among those exposed, the vaccine demonstrated more than 70% efficacy—strong enough for Pfizer to proceed.

Pfizer’s vaccine chief Annaliesa Anderson described the results as “highly encouraging,” signaling confidence that regulators may still view the data favorably.

A Potential First-in-Class Opportunity

Pfizer is moving forward with plans to seek regulatory approval for its Lyme disease vaccine candidate, even after the shot failed to meet the statistical endpoint in a late-stage clinical trial. The decision underscores the company’s confidence in the vaccine’s real-world potential—and highlights the complexities of vaccine development.

Why the Trial “Failed”—But Still Matters

The vaccine, developed with partner Valneva, did not meet its primary statistical endpoint because too few participants in the trial actually contracted Lyme disease.

This made it difficult to achieve the statistical certainty regulators typically require. However, among those exposed, the vaccine demonstrated more than 70% efficacy—strong enough for Pfizer to proceed.

Pfizer’s vaccine chief Annaliesa Anderson described the results as “highly encouraging,” signaling confidence that regulators may still view the data favorably.

A Potential First-in-Class Opportunity

The vaccine targets a protein found on the surface of Lyme-causing bacteria. It trains the immune system to produce antibodies that can neutralize the bacteria inside the tick before transmission to humans occurs.

The regimen includes three initial doses followed by a booster, designed to maintain long-term protection.

Bottom Line

Pfizer’s decision to move forward reflects a calculated risk: betting that strong efficacy signals outweigh statistical shortcomings.

If regulators agree, the vaccine could mark a long-awaited breakthrough in Lyme disease prevention. If not, it may highlight the limits of flexibility in clinical standards—especially in today’s more cautious regulatory environment.